Ghasem Zarei, Zahra Pezeshki, Samira Choopani, Mehdi Nematbakhsh
{"title":"Octreotide and direct/indirect lung injury.","authors":"Ghasem Zarei, Zahra Pezeshki, Samira Choopani, Mehdi Nematbakhsh","doi":"10.4103/RPS.RPS_67_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and purpose: </strong>Lung injury is one of the most important diseases, which is accompanied by hypoxemia, organ failure, and a high mortality rate. There are several symptoms and causes of lung injuries. In the past years, special attention has been given to investigating the pathophysiology and the treatment of this disease. Octreotide, as an anti-inflammatory, anti-secretory, tissue-repairing, and anti-fibrotic drug, has been considered and administered for the treatment of lung injury. This review article considered the pharmacological effects of octreotide on physiopathological conditions in patients or animal models that have direct or indirect lung injury.</p><p><strong>Search strategy and findings: </strong>Keywords including \"octreotide\" OR \"sandostatin\" AND \"lung injury\" OR \"ARDS\" OR \"respiratory distress\" OR \"lung fibrosis\" were searched in the database of PubMed, and 44 articles were found. According to the direct or indirect lung injury, the articles were classified.</p><p><strong>Conclusion: </strong>It appears that octreotide is a protective drug for the treatment of direct and indirect lung injuries, exhibiting anti-inflammatory, anti-hypersecretory, anti-fibrotic, and anti-neutrophil permeability effects, while also increasing endogenous antioxidants. However, there is still room for extensive research to fully clarify the effectiveness of octreotide for direct or indirect lung injury.</p>","PeriodicalId":21075,"journal":{"name":"Research in Pharmaceutical Sciences","volume":"20 4","pages":"469-484"},"PeriodicalIF":2.1000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12419580/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research in Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/RPS.RPS_67_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background and purpose: Lung injury is one of the most important diseases, which is accompanied by hypoxemia, organ failure, and a high mortality rate. There are several symptoms and causes of lung injuries. In the past years, special attention has been given to investigating the pathophysiology and the treatment of this disease. Octreotide, as an anti-inflammatory, anti-secretory, tissue-repairing, and anti-fibrotic drug, has been considered and administered for the treatment of lung injury. This review article considered the pharmacological effects of octreotide on physiopathological conditions in patients or animal models that have direct or indirect lung injury.
Search strategy and findings: Keywords including "octreotide" OR "sandostatin" AND "lung injury" OR "ARDS" OR "respiratory distress" OR "lung fibrosis" were searched in the database of PubMed, and 44 articles were found. According to the direct or indirect lung injury, the articles were classified.
Conclusion: It appears that octreotide is a protective drug for the treatment of direct and indirect lung injuries, exhibiting anti-inflammatory, anti-hypersecretory, anti-fibrotic, and anti-neutrophil permeability effects, while also increasing endogenous antioxidants. However, there is still room for extensive research to fully clarify the effectiveness of octreotide for direct or indirect lung injury.
期刊介绍：
Research in Pharmaceutical Sciences (RPS) is included in Thomson Reuters ESCI Web of Science (searchable at WoS master journal list), indexed with PubMed and PubMed Central and abstracted in the Elsevier Bibliographic Databases. Databases include Scopus, EMBASE, EMCare, EMBiology and Elsevier BIOBASE. It is also indexed in several specialized databases including Scientific Information Database (SID), Google Scholar, Iran Medex, Magiran, Index Copernicus (IC) and Islamic World Science Citation Center (ISC).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
